Compare Illumina, Inc. (ILMN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Chase & Co — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while JPMorgan Chase & Co trades at $332.2 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 22.1× Illumina, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and JPMorgan Chase & Co for 127 Days on average.
| ILMN | JPM | |
|---|---|---|
Market Cap | $39.95B | $880.98B |
Volume | 3,169,503 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $293.69 | $365.18 |
52-Week Low | $91.00 | $282.84 |
Typical Hold Time | 83 Days | 127 Days |
Enterprise Value | $41.31B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
JPMorgan Chase (JPM) trades at $329.58, down 0.51% on the day, with a bearish technical signal. The stock shows strong fundamentals, with a P/E of 14.12 and net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 was a miss. Analyst consensus is a Moderate Buy with a $373.18 price target, implying potential upside. Cash flow trends show significant financing activities offsetting negative operating cash flows.
The outlook for JPM is positive based on robust profitability and analyst support, but risks include volatile cash flows, geopolitical tensions affecting banking sectors, and CEO warnings on economic challenges. The stock's current price near support at $327 suggests a potential entry point for long-term investors, though near-term bearish technicals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
